

Appendix: Tables

1.	Sales January to September 2025 and 2024	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2025 and 2024	3
3.	Product sales Pharmaceuticals Division and constant exchange rate growth YTD September 2025 vs. YTD September 2024	4
4.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth	6
5.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States	7
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe	8
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan	9
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International	10

1. Sales January to September 2025 and 2024

CHF millions	Nine months ended 30 September		% change	
	2025	2024	At CER	In CHF
Pharmaceuticals Division	35,555	34,257	9	4
United States	18,798	18,166	8	3
Europe	6,818	6,613	5	3
Japan	2,139	2,083	5	3
International	7,800	7,395	13	5
Diagnostics Division	10,307	10,727	1	-4
Roche Group	45,862	44,984	7	2

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2025 and 2024

CHF millions	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024
Pharmaceuticals Div.	11,620	10	11,914	12	11,949	8	12,036	11	11,570	7
United States	6,284	9	6,608	15	6,224	6	6,446	13	6,128	5
Europe	2,188	2	2,219	10	2,320	5	2,246	5	2,252	5
Japan	717	1	791	1	671	3	754	7	714	6
International	2,431	22	2,296	11	2,734	18	2,590	11	2,476	11
Diagnostics Division	3,516	6	3,597	-1	3,491	0	3,468	0	3,348	2
Roche Group	15,136	9	15,511	9	15,440	6	15,504	8	14,918	6

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

3. Product sales Pharmaceuticals Division and constant exchange rate growth YTD September 2025 vs. YTD September 2024

CHF millions	Total		United States		Europe		Japan		International	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Ocrevus	5,190	7	3,613	4	1,060	12	-	-	517	24
Hemlibra	3,526	12	1,941	7	740	9	275	9	570	45
Vabysmo	3,063	13	2,139	4	556	24	105	26	263	115
Tecentriq	2,616	1	1,222	-3	650	2	262	-3	482	15
Perjeta	2,316	-13	968	-2	418	-15	54	-39	876	-19
Xolair	2,226	34	2,226	34	-	-	-	-	-	-
Actemra/RoActemra	1,893	2	926	2	450	-10	230	5	287	19
Phesgo	1,827	54	523	35	602	13	139	63	563	193
Kadcyla	1,531	8	577	5	396	-6	68	-2	490	28
Evrysdi	1,293	8	468	14	450	5	68	6	307	5
Alecensa	1,190	8	420	18	197	-8	151	8	422	7
Polivy	1,101	40	497	27	228	63	153	10	223	94
MabThera/Rituxan	933	-4	575	-2	104	-2	11	-11	243	-9
Activase/TNKase	833	-2	797	-2	-	-	-	-	36	-13
Herceptin	817	-19	175	-9	223	0	6	-46	413	-29
Avastin	763	-15	225	-19	54	-14	111	-23	373	-10
Gazyva	728	13	376	18	183	1	25	20	144	17
Pulmozyme	361	16	254	25	49	-10	-	-8	58	8
CellCept	292	7	14	-11	97	22	34	28	147	-2
Madopar	273	3	-	-	70	-3	-	-	203	6
Enspryng	269	26	71	13	30	39	120	17	48	73
Xofluza	248	163	32	*	2	*	-	-	214	140
Elevidys	221	64	-	-	-	-	-	-	221	64

Columvi	202	81	125	97	43	66	-	-	34	51
Rozlytrek	114	22	37	3	17	10	5	-12	55	51
Lunsumio	77	47	45	15	16	25	12	-	4	*
Itovebi	68	-	61	-	1	-	-	-	6	-
Luxturna	39	178	39	178	-	-	-	-	-	-
Cotellic	35	22	16	41	8	-6	-	-	11	22
PiaSky	33	328	-	5	5	-	27	271	1	-
Susvimo	6	117	6	117	-	-	-	-	-	-
Ronapreve	-	-100	-	-	-	-100	-	-	-	-100
Pharma other	1,471	-9	430	-6	169	-14	283	-2	589	-13

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others

* Over 500%

4. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024
Ocrevus	1,697	11	1,688	7	1,778	6	1,728	10	1,684	6
Hemlibra	1,137	14	1,223	21	1,165	11	1,256	22	1,105	4
Vabysmo	1,022	59	1,048	43	1,018	18	1,049	19	996	4
Tecentriq	905	0	937	-1	870	0	863	-1	883	4
Perjeta	888	2	807	9	840	-10	773	-14	703	-14
Xolair	627	12	733	29	645	26	800	41	781	34
Actemra/RoActemra	672	7	697	4	619	-1	660	8	614	-2
Phesgo	445	55	496	72	593	52	604	57	630	51
Kadcyla	495	7	504	9	506	5	531	12	494	7
Evrysdi	408	13	385	10	420	18	449	-1	424	10
Alecensa	385	7	397	8	397	11	405	6	388	8
Polivy	304	24	304	34	358	42	372	51	371	30
MabThera/Rituxan	317	-14	356	-2	298	-16	332	1	303	3
Activase/TNKase	302	9	307	15	297	-2	253	-7	283	1
Herceptin	323	-13	318	-10	292	-20	268	-23	257	-15
Avastin	289	-19	290	-17	274	-15	248	-19	241	-11
Gazyva	225	8	240	25	249	15	241	12	238	13
Pulmozyme	104	4	126	18	123	10	116	13	122	26
CellCept	86	-5	116	23	98	4	98	1	96	18
Madopar	78	-9	90	15	92	2	101	1	80	8

5. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

[illegible]

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024
Ocrevus	322	11	345	21	344	11	362	14	354	12
Hemlibra	222	3	236	15	247	7	246	7	247	14
Vabysmo	167	104	168	88	197	42	181	25	178	9
Tecentriq	220	-3	214	0	220	5	214	1	216	0
Perjeta	161	-19	144	-9	144	-16	138	-15	136	-14
Xolair	-	-	-	-	-	-	-	-	-	-
Actemra/RoActemra	145	-26	150	-21	152	-19	156	-7	142	-1
Phesgo	189	33	195	32	199	18	202	13	201	9
Kadcyla	140	-5	136	5	135	-7	131	-5	130	-5
Evrysdi	149	13	137	3	145	6	147	3	158	7
Alecensa	72	0	67	-5	68	-6	65	-7	64	-10
Polivy	56	2	50	38	94	74	66	119	68	21
MabThera/Rituxan	32	-29	41	6	35	-10	35	-6	34	13
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Herceptin	73	-16	76	-6	77	0	73	-2	73	2
Avastin	19	-9	22	13	14	-33	12	-46	28	47
Gazyva	62	-1	60	11	60	-3	61	4	62	1
Pulmozyme	16	-11	18	-2	18	-9	16	-16	15	-3
CellCept	21	-30	43	51	34	7	31	17	32	49
Madopar	23	-3	24	-1	23	-1	23	-9	24	0

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024
Ocrevus	-	-	-	-	-	-	-	-	-	-
Hemlibra	88	4	108	22	82	3	101	12	92	11
Vabysmo	33	40	39	46	32	35	38	28	35	17
Tecentriq	95	0	103	2	81	-5	93	-2	88	-1
Perjeta	26	-48	24	-53	18	-51	19	-35	17	-27
Xolair	-	-	-	-	-	-	-	-	-	-
Actemra/RoActemra	79	11	84	11	71	5	81	6	78	4
Phesgo	38	-	48	*	40	115	50	59	49	41
Kadcyla	25	7	27	10	21	-3	24	0	23	-2
Evrysdi	22	2	27	9	20	0	26	9	22	7
Alecensa	48	2	54	4	49	12	51	-1	51	13
Polivy	51	-9	55	-3	44	2	55	14	54	14
MabThera/Rituxan	3	-30	5	-22	3	-17	4	-12	4	-3
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Herceptin	3	-56	3	-57	2	-56	2	-46	2	-30
Avastin	47	-32	48	-28	36	-30	40	-21	35	-19
Gazyva	6	-17	8	-10	8	46	9	3	8	22
Pulmozyme	1	2	-	32	-	-26	-	-11	-	13
CellCept	9	-7	13	13	12	38	12	33	10	13
Madopar	-	-	-	-	-	-	-	-	-	-

* Over 500%

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International

CHF millions	Q3 2024	% change vs. Q3 2023	Q4 2024	% change vs. Q4 2023	Q1 2025	% change vs. Q1 2024	Q2 2025	% change vs. Q2 2024	Q3 2025	% change vs. Q3 2024
Ocrevus	146	23	164	37	187	16	151	23	179	35
Hemlibra	152	64	131	36	226	72	195	60	149	9
Vabysmo	47	180	47	63	71	101	98	130	94	111
Tecentriq	163	32	182	5	158	21	148	7	176	17
Perjeta	366	25	323	9	336	-9	281	-27	259	-21
Xolair	-	-	-	-	-	-	-	-	-	-
Actemra/RoActemra	94	52	81	26	102	26	98	25	87	7
Phesgo	72	87	87	129	175	142	183	230	205	213
Kadcyla	137	20	150	25	149	21	181	33	160	28
Evrysdi	91	8	62	-9	95	56	127	-15	85	4
Alecensa	129	4	123	4	150	12	143	2	129	8
Polivy	42	42	41	70	64	80	80	94	79	105
MabThera/Rituxan	89	-7	83	-11	79	-23	87	2	77	-5
Activase/TNKase	13	-16	17	5	12	-9	11	-37	13	18
Herceptin	184	-6	175	-9	153	-29	132	-34	128	-25
Avastin	133	-14	126	-16	144	-3	120	-15	109	-13
Gazyva	41	7	42	31	50	11	49	18	45	24
Pulmozyme	15	32	18	18	21	-10	17	7	20	34
CellCept	51	13	54	16	47	-4	51	-8	49	7
Madopar	55	-11	66	21	69	3	78	4	56	11

International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian Sub-Continent), Latin America, Middle East, Africa, Canada, others